Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)

NCT06420908 · clinicaltrials.gov ↗

NA

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped The primary reason for termination was difficulty in recruitment

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Adebrelimab+TP/FP+ radiation therapy
DRUG: Adebrelimab+FP/TP+ radiation therapy

Sponsor

Hebei Medical University Fourth Hospital